Reliability of the electronic early treatment diabetic retinopathy study testing protocol in children 7 to <13 years old

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Download Full-text

Treatment Patterns and Clinical Outcomes for Branch Retinal Vein Occlusion: An 8-Year Experience at a Tertiary Eye Center

Journal of VitreoRetinal Diseases ◽

10.1177/2474126420978874 ◽

2021 ◽

pp. 247412642097887

Author(s):

Terry Lee ◽

Cason B. Robbins ◽

Akshay S. Thomas ◽

Sharon Fekrat

Keyword(s):

Visual Acuity ◽

Diabetic Retinopathy ◽

Retinal Vein Occlusion ◽

Real World ◽

Early Treatment ◽

Branch Retinal Vein Occlusion ◽

Treatment Patterns ◽

Vein Occlusion ◽

Anti Vegf ◽

Treatment Naïve

Purpose: This work aims to investigate real-world treatment patterns and outcomes in eyes with branch retinal vein occlusion in the antivascular endothelial growth factor (anti-VEGF) era. Methods: A retrospective, nonrandomized, comparative study was conducted on eyes diagnosed with branch retinal vein occlusion at a single tertiary center between 2009 and 2017. Medical history, treatment patterns, and visual acuity outcomes were examined. Subanalysis was performed for eyes that met the eligibility criteria for the BRAVO (Ranibizumab for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion) trial. Results: A total of 315 eyes were included, of which 244 were treatment naive. In all eyes, the most common first treatment was the following: intravitreal bevacizumab (38.4%), aflibercept (15.1%), ranibizumab (8.1%), sectoral scatter laser (6.2%), and triamcinolone (3.1%). At 1 year, treatment-naive eyes had received an average of 2.43 anti-VEGF injections. During follow-up, treatment-naive eyes gained an average of 0.21 Early Treatment Diabetic Retinopathy Study lines. Forty eyes that met BRAVO trial criteria received an average of 5.05 anti-VEGF injections in the first year and gained an average of 1.83 Early Treatment Diabetic Retinopathy Study lines. Conclusions: This real-world cohort received fewer anti-VEGF injections at year 1 and experienced less improvement in visual acuity during the course of treatment than clinical trial participants. Trial-eligible patients received more injections and had greater visual gains than those who would not have been eligible for the trial.

Download Full-text

Minimum Detectable Change of Visual Acuity Measurements Using ETDRS Charts (Early Treatment Diabetic Retinopathy Study)

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18157876 ◽

2021 ◽

Vol 18 (15) ◽

pp. 7876

Author(s):

María Carmen Sánchez-González ◽

Raquel García-Oliver ◽

José-María Sánchez-González ◽

María-José Bautista-Llamas ◽

José-Jesús Jiménez-Rejano ◽

...

Keyword(s):

Visual Acuity ◽

Diabetic Retinopathy ◽

Early Treatment ◽

High Reliability ◽

Minimal Detectable Change ◽

High Contrast ◽

Detectable Change ◽

Low Contrast ◽

Minimum Detectable Change ◽

The Mean

In our work, we determined the value of visual acuity (VA) with ETDRS charts (Early Treatment Diabetic Retinopathy Study). The purpose of the study was to determine the measurement reliabilities, calculating the correlation coefficient interclass (ICC), the value of the error associated with the measure (SEM), and the minimal detectable change (MDC). Forty healthy subjects took part. The mean age was 23.5 ± 3.1 (19 to 26) years. Visual acuities were measured with ETDRS charts (96% ETDRS chart nº 2140) and (10% SLOAN Contrast Eye Test chart nº 2153). The measurements were made (at 4 m) under four conditions: Firstly, photopic conditions with high contrast (HC) and low contrast (LC) and after 15 min of visual rest, mesopic conditions with high and low contrast. Under photopic conditions and high contrast, the ICC = 0.866 and decreased to 0.580 when the luminosity and contrast decreased. The % MDC in the four conditions was always less than 10%. It was minor under photopic conditions and HC (5.83) and maximum in mesopic conditions and LC (9.70). Our results conclude a high reliability of the ETDRS test, which is higher in photopic and high contrast conditions and lower when the luminosity and contrast decreases.

Download Full-text

Comparison of Ultrawide Field Imaging and Standard Imaging in Assessment of Early Treatment Diabetic Retinopathy Severity Scale

Ophthalmology Science ◽

10.1016/j.xops.2021.100029 ◽

2021 ◽

pp. 100029

Author(s):

Amitha Domalpally ◽

Nancy Barrett ◽

James Reimers ◽

Barbara Blodi

Keyword(s):

Diabetic Retinopathy ◽

Early Treatment ◽

Severity Scale ◽

Field Imaging ◽

Ultrawide Field Imaging

Download Full-text

Προσδιορισμός του παράγοντα ενεργοποίησης των αιμοπεταλίων (PAF) στο αίμα ασθενών με διαβητική αμφιβληστροειδοπάθεια

10.12681/eadd/39928 ◽

2017 ◽

Author(s):

Παναγιώτης Πανταζής

Keyword(s):

Diabetic Retinopathy ◽

Proliferative Diabetic Retinopathy ◽

Early Treatment ◽

Platelet Activating Factor ◽

Paf Acetylhydrolase ◽

One Way Anova

Εισαγωγή: Η διαβητική αμφιβληστροειδοπάθεια αποτελεί τη σοβαρότερη οφθαλμολογική επιπλοκή του σακχαρώδους διαβήτη, πλήττοντας 93 εκατομμύρια διαβητικούς ασθενείς παγκοσμίως. Ο Παράγοντας Ενεργοποίησης των Αιμοπεταλίων (Platelet activating factor, PAF) αποτελεί ένα φωσφολιπίδιο χαμηλού μοριακού βάρους και ενοχοποιείται για την αύξηση της αγγειακής διαπερατότητας και τη νεοαγγείωση, που παρατηρούνται στη διαβητική αμφιβληστροειδοπάθεια και σε άλλες οφθαλμικές παθήσεις.Στόχος: Η εκτίμηση του ρόλου της εξωκυττάριας (πλάσματος) ακετυλ-υδρολάσης του PAF (PAF acetylhydrolase, PAF-AH) στην παθογένεια και την εξέλιξη της διαβητικής αμφιβληστροειδοπάθειας.Μεθοδολογία: Εξήντα οκτώ διαβητικοί και 23 υγιή άτομα ανάλογης ηλικίας υπεβληθήκαν σε αιμοληψία και μετρήθηκε η δραστηριότητα της PAF-AH στο πλάσμα των συμμετεχόντων. Οι διαβητικοί ασθενείς ταξινομήθηκαν περεταίρω σε δύο ομάδες με βάσει το σύστημα ETDRS (Early Treatment Diabetic Retinopathy Study), με τη βοήθεια της έμμεσης οφθαλμοσκόπησης και της φλουοροαγγειογραφίας. Τριάντα επτά ασθενείς με μη παραγωγική διαβητική αμφιβληστροειδοπάθεια (non-proliferative diabetic retinopathy, NPDR) και 31 ασθενείς με παραγωγική διαβητική αμφιβληστροειδοπάθεια (proliferative diabetic retinopathy, PDR) συμπεριελήφθησαν τελικά στη μελέτη. Αποτελέσματα: Η δραστικότητα της PAF-AH του πλάσματος βρέθηκε αυξημένη στους διαβητικούς ασθενείς σε σχέση με την ομάδα των υγιών (υγιείς: 0.114µmol/min/ml, NPDR: 0.147µmol/min/ml and PDR: 0.206µmol/min/ml) και οι διαφορές των μέσω τιμών ήταν στατιστικά σημαντικές ανάμεσα στις τρεις ομάδες [One-Way ANOVA, p<0.0001, F= 10 (2,88)].Συμπεράσματα: Η δραστικότητα της PAF-AH του πλάσματος αυξάνεται παράλληλα με τη βαρύτητα της διαβητικής αμφιβληστροειδοπάθειας.

Download Full-text